23andMe Enters Definitive Agreement with TTAM Research Institute for $305 Million Asset Sale

23andMe Holding Co., a leading human genetics and biotechnology company, has announced the sale of substantially all its assets to TTAM Research Institute, a nonprofit public benefit corporation. The deal, valued at $305 million, was finalized following a competitive bidding process that included Regeneron Pharmaceuticals as the backup bidder. The transaction, which requires approval by the U.S. Bankruptcy Court for the Eastern District of Missouri, includes 23andMe’s Personal Genome Service, Research Services, and Lemonaid Health business lines. TTAM, led by 23andMe co-founder Anne Wojcicki, has pledged to uphold 23andMe's existing privacy policies while introducing further consumer data protections. These measures include honoring data deletion requests, restricting data transfers, and establishing a Consumer Privacy Advisory Board. The transaction, expected to close shortly pending court approval, marks a significant transition for 23andMe as it continues its mission under new stewardship while ensuring data privacy and consumer trust.